BioCentury | Jul 11, 2018
Translation in Brief

Poisoning the stromal chalice

A study published in the Journal of Clinical Investigation suggests antibody-drug conjugates targeting the tumor stroma could treat cancers by co-opting a stromal mechanism to feed cytotoxic drugs to the surrounding tumor cells. Tumor-associated stroma,...
BioCentury | Jun 13, 2018
Distillery Therapeutics


INDICATION: Solid tumors; pancreatic cancer; colorectal cancer; breast cancer; lung cancer; ovarian cancer Patient sample and mouse studies suggest anti-ANTXR1 antibody-drug conjugates (ADCs) could help treat solid tumors. In tissue samples from esophageal, kidney, uterine,...
BioCentury | Dec 5, 2017
Distillery Therapeutics


INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest chimeric antigen receptor (CAR) T cells targeting ANTXR1 could help treat triple-negative breast cancer (TNBC). In patient samples, levels of ANTXR1 were higher in...
BioCentury | Nov 2, 2016
Distillery Techniques


TECHNOLOGY: Computational models A computational model for predicting how mutations alter activity could aid the design of therapies that overcome drug resistance. For any protein-compound pair, the model utilizes molecular dynamic simulations to build a...
BioCentury | Jul 9, 2015
Distillery Therapeutics

Therapeutics: Ras homolog enriched in striatum (RHES; RASD2; TEM2)

...weight loss compared with normal RHES expression. In two mouse models of HD with homozygous RHES...
...expression. In two mouse models of HD with homozygous RHES knockout, viral vector-mediated expression of RHES...
...vitro cell-based assays of RHES activity to screen for inhibitors. TARGET/MARKER/PATHWAY: Ras homolog enriched in striatum (RHES; RASD2 ; TEM2...
BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Mammalian target of rapamycin complex 1 (mTORC1); RASD family member 2 (RASD2; Rhes; TEM2)

...and normal mice. In the mouse model, viral vector-induced expression of the mTOR signaling activator RASD2...
...Mammalian target of rapamycin complex 1 (mTORC1) ; RASD family member 2 (RASD2; Rhes ; TEM2...
BioCentury | Apr 24, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer CD248 endosialin (TEM1) Mouse studies suggest a DNA plasmid encoding a TEM1-tetanus toxoid (TT) fusion peptide could be used as a cancer vaccine. TEM1...
BioCentury | Apr 17, 2014
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Tumor endothelial marker (TEM)-expressing circulating endothelial cells (CECs) as a blood-based marker to detect tumors and monitor response to antiangiogenic therapy Studies in human...
BioCentury | Oct 14, 2013
Clinical News

MORAb-004: Phase I started

Eisai's Morphotek Inc. subsidiary said the Children's Oncology Group began an open-label, U.S. Phase I trial to evaluate IV MORAb-004 once weekly in about 65 pediatric patients with recurrent or refractory solid tumors. Morphotek has...
BioCentury | Aug 13, 2012
Clinical News

MORAb-004: Phase II started

Eisai disclosed in its 1Q12 earnings ending June 30 that it began a double-blind, placebo-controlled international Phase II trial to evaluate MORAb-004 in combination with gemcitabine and docetaxel in about 200 patients with metastatic soft...
Items per page:
1 - 10 of 36